News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Get News Alerts by Email

Aug 21, 2017

First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia
Aug 2, 2017

Astellas Announces Leadership Changes in Corporate Affairs Organization

Moyra Knight, Andrew Lewis and Karl Uhlendorf named to key roles
- Photos 3
Jul 28, 2017

Astellas Reports First Quarter FY2017 Financial Results
Jul 26, 2017

Astellas Announces Wind-Down of Agensys Research Operations

Astellas to Retain Certain Promising Antibody-Drug Conjugate R&D Programs of Agensys
Jul 20, 2017

U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia
Jul 19, 2017

Astellas Farma Brasil named a top-ten pharmaceutical company to work for in Brazil

Astellas recognized by Great Place to Work® Institute
- Photos 1
Jul 17, 2017

Astellas Commitment to Creating Sustainable Community Impact Highlighted in Americas Corporate Social Responsibility Report Card 2016
- Photos 1
Jul 13, 2017

Astellas Head of Medical Affairs Americas Shontelle Dodson Joins National Pharmaceutical Council Board of Directors
- Photos 1
Jul 12, 2017

Astellas Announces Leadership Changes in US Commercial Organization

David Musselman and Lynn Gerber named to key regional sales roles
- Photos 3
Jul 6, 2017

Astellas Employees Support Veterans at 2017 Warrior Games

Initiative part of Astellas’ ongoing commitment to communities, veterans and their families through its Living Smart social responsibility platform
- Photos 1

Show per page